GoAI
Get started
Alzamend Neuro Inc logo

Alzamend Neuro Inc

ALZN

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$1.56

−$0.07 · -4.29%

Aug 21, 4:00 PM ET

ALZN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

44

Fair Value

Momentum

31

Weakening

Sentiment

60

Mixed

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Stephan Jackman
Listed since
Jun 15, 2021
Employees
6

Market position

Day range

Current $1.56

52-week range

Current $1.56

Open
$1.57
Previous close
$1.63
Volume
244.13K
1.96× average
Average volume
124.42K
Average daily volume
Market cap
5.94M USD
Beta
0.19
Market reference 1
50-day average
$1.3115
+18.95% above average
200-day average
$1.6371
-4.71% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
3.09M USD
EV / EBITDA
-0.36×
Earnings yield
-230.59%
Free cash flow yield
-212.07%

Profitability & efficiency

Return on equity
-1196.43%
Return on assets
-421.88%
Return on invested capital
-1195.68%

Financial health

Current ratio
1.31×

Financial statements

Income trends

Operating income

−8.77M USD-94.96%

Net income

−8.77M USD-94.30%
Income trends across reported periods−3.46M USD−7.61M USD−11.76M USD−15.92M USDOperating income, FY2022: −12.32M USDOperating income, FY2023: −14.87M USDOperating income, FY2024: −9.94M USDOperating income, FY2025: −4.5M USDOperating income, FY2026: −8.77M USDNet income, FY2022: −12.36M USDNet income, FY2023: −14.88M USDNet income, FY2024: −9.95M USDNet income, FY2025: −4.51M USDNet income, FY2026: −8.77M USDFY2022FY2023FY2024FY2025FY2026
Operating income FY2022 −12.32M USD. Operating income FY2023 −14.87M USD. Operating income FY2024 −9.94M USD. Operating income FY2025 −4.5M USD. Operating income FY2026 −8.77M USD. Net income FY2022 −12.36M USD. Net income FY2023 −14.88M USD. Net income FY2024 −9.95M USD. Net income FY2025 −4.51M USD. Net income FY2026 −8.77M USD.
Metric (USD)FY2026FY2025FY2024FY2023FY2022
Research and development3.63M USD1.41M USD6.46M USD7.45M USD5.2M USD
Selling, general, and administrative5.14M USD3.08M USD3.48M USD7.42M USD7.12M USD
Operating expenses8.77M USD4.5M USD9.94M USD14.87M USD12.32M USD
Interest income1.08K USD————
Interest expense−6.62K USD18.03K USD10.1K USD7.7K USD46.52K USD
Depreciation and amortization110.74K USD50.74K USD50.74K USD23.07K USD3.55K USD
Operating income−8.77M USD−4.5M USD−9.94M USD−14.87M USD−12.32M USD
Net income−8.77M USD−4.51M USD−9.95M USD−14.88M USD−12.36M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
-463.24%
11 comparable reports
Latest EPS result
-0.74
Estimate -0.67 · Miss by 10.45%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.25-7.87-15.49-23.11Q4 '24BeatQ1 '25BeatQ3 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ3 '26MissQ3 '26Estimate
Q4 2024, reported Dec 11, 2024: actual -3.6, estimate -21.42, surprise +83.19%, Beat. Q1 2025, reported Mar 10, 2025: actual -1.71, estimate -2.61, surprise +34.48%, Beat. Q3 2025, reported Jul 29, 2025: actual -2.36, estimate -2.7, surprise +12.59%, Beat. Q3 2025, reported Sep 10, 2025: actual -1.28, estimate -3.69, surprise +65.31%, Beat. Q4 2025, reported Dec 9, 2025: actual -0.3, estimate -0.83, surprise +63.86%, Beat. Q1 2026, reported Mar 11, 2026: actual -0.58, estimate -0.53, surprise -9.43%, Miss. Q3 2026, reported Jul 22, 2026: actual -0.74, estimate -0.67, surprise -10.45%, Miss. Q3 2026, reported Sep 9, 2026: actual —, estimate -0.56, surprise —, Comparison unavailable.

ALZN peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ALZN

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
9.9K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research ALZN

research.disclaimer